In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Chief Counsel Warning Letter Review To Continue After Troy’s Departure

This article was originally published in The Gray Sheet

Executive Summary

The FDA Office of Chief Counsel's review of warning and untitled letters has resulted in the rejection of approximately 5% of letters, outgoing Chief Counsel Daniel Troy said

You may also be interested in...



FDA Chief Counsel Bradshaw Brings DoJ Experience, Utah Political Ties

Sheldon Bradshaw brings high-level government experience and strong political connections to the top legal position at FDA

FDA Chief Counsel Bradshaw Brings DoJ Experience, Utah Political Ties

Sheldon Bradshaw brings high-level government experience and strong political connections to the top legal position at FDA

Troy joins Sidley Austin Brown & Wood

Former FDA Chief Counsel Dan Troy accepts position in firm's Life Sciences Practice & Appellate Litigation Group. He will focus on administrative and constitutional law and litigation, especially for the pharmaceutical, medical device and biotechnology industries, according to a Jan. 6 release. Colleen Klasmeier, who served as special assistant to the chief counsel under Troy, also is joining Sidley's Life Sciences Practice. Gerald Masoudi, formerly with Kirkland & Ellis, replaced Troy at FDA in November (1"The Gray Sheet" Nov. 22, 2004, p. 4)...

Related Content

UsernamePublicRestriction

Register

MT021207

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel